Department of General Internal Medicine and Palliative Care Team,Teine Keijinkai Hospital, 12-1-40, Maeda 1jyo, Sapporo 006-8558, Japan.
Jpn J Clin Oncol. 2013 Sep;43(9):896-909. doi: 10.1093/jjco/hyt099. Epub 2013 Jul 23.
Pain is the most frequent and distressing symptom in cancer patients. As part of a worldwide effort to improve the quality of pain control, several clinical guidelines for the management of cancer pain have been published and revised in the last decade. The Japanese Society of Palliative Medicine first published a Japanese clinical guideline for the management of cancer pain in 2000. Since then, many clinical studies concerning cancer pain management have been conducted, new drugs have become available in Japan and the methodology of developing a guideline has been refined. Therefore, we decided to develop a novel clinical guideline. This review paper summarizes the recommendations and the rationales of this new clinical guideline for the pharmacological management of cancer pain. In addition, a short summary of the clinical guideline development process is provided. This new Japanese Society of Palliative Medicine guideline highlights the importance of conducting well-designed studies to identify the best practices in cancer pain management.
疼痛是癌症患者最常见和最痛苦的症状。作为全球努力改善疼痛控制质量的一部分,过去十年中已经发布并修订了几项癌症疼痛管理的临床指南。日本缓和医疗学会于 2000 年首次发布了日本癌症疼痛管理临床指南。此后,许多关于癌症疼痛管理的临床研究已经开展,日本出现了新的药物,指南制定方法也得到了改进。因此,我们决定制定一个新的临床指南。本文综述了该新临床指南中关于癌症疼痛药物治疗的建议及其依据。此外,还简要介绍了指南制定过程。日本缓和医疗学会的这个新指南强调了开展精心设计的研究以确定癌症疼痛管理最佳实践的重要性。